Stocks
Roivant Sciences Ltd.ROIV
NASDAQHealthcareBiotechnology$40.82-1.72%
Price as of · delayed, not real-time
Focused on developing innovative therapeutics through a decentralized model, this biopharmaceutical company leverages subsidiary 'Vants' to accelerate drug development across multiple disease areas. Investors monitor its pipeline progress and partnerships with major pharma firms given its unique approach to reducing R&D inefficiencies.
Market Cap: $20.1B52W Range: $13.81-$42.50
Congressional Interest in Roivant Sciences Ltd. (ROIV)
1 member of Congress has disclosed 4 trades in Roivant Sciences Ltd. (ROIV), a Healthcare company. The buy/sell breakdown shows 2 purchases versus 2 sales. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
4
Unique Politicians
1
Buys
2
Sells
2
Who in Congress Is Trading ROIV?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2025-10-31 | Lisa McClain | sell | $1K-$15K |
| 2025-10-30 | Lisa McClain | sell | $1K-$15K |
| 2025-10-30 | Lisa McClain | buy | $1K-$15K |
| 2025-06-17 | Lisa McClain | buy | $1K-$15K |